Caladrius Biosciences Inc.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal ca… Read more
Market Cap & Net Worth: Caladrius Biosciences Inc. (0HS8)
Caladrius Biosciences Inc. (LSE:0HS8) has a market capitalization of $50.12K ($50.12K) as of March 18, 2026. Listed on the LSE stock exchange, this UK-based company holds position #22830 globally and #412 in its home market, demonstrating a 0.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Caladrius Biosciences Inc.'s stock price $5.04 by its total outstanding shares 9944 (9.94K).
Caladrius Biosciences Inc. Market Cap History: 2018 to 2026
Caladrius Biosciences Inc.'s market capitalization history from 2018 to 2026. Data shows change from $53.90K to $50.12K (-1.59% CAGR).
Caladrius Biosciences Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Caladrius Biosciences Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0HS8 by Market Capitalization
Companies near Caladrius Biosciences Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Caladrius Biosciences Inc. by market ranking:
- Davolink Inc. (KQ:340360): Ranked #22821 globally with a market cap of $35.69 Million USD ( ₩52.26 Billion KRW).
- R. Stahl AG NA O.N. (F:RSL2): Ranked #22822 globally with a market cap of $35.68 Million USD ( €34.76 Million EUR).
- Vente Unique.com (PA:ALVU): Ranked #22831 globally with a market cap of $35.59 Million USD ( €34.68 Million EUR).
- Nyrada Inc (AU:NYR): Ranked #22832 globally with a market cap of $35.58 Million USD ( AU$57.47 Million AUD).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #22821 | Davolink Inc. | KQ:340360 | $35.69 Million | ₩2030.00 |
| #22822 | R. Stahl AG NA O.N. | F:RSL2 | $35.68 Million | €13.10 |
| #22831 | Vente Unique.com | PA:ALVU | $35.59 Million | €15.00 |
| #22832 | Nyrada Inc | AU:NYR | $35.58 Million | AU$0.53 |
Caladrius Biosciences Inc. Historical Marketcap From 2018 to 2026
Between 2018 and today, Caladrius Biosciences Inc.'s market cap moved from $53.90K to $ 50.12K, with a yearly change of -1.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $50.12K | +161.14% |
| 2025 | $19.19K | -35.93% |
| 2024 | $29.95K | +5.76% |
| 2023 | $28.32K | +17.25% |
| 2022 | $24.15K | +182.56% |
| 2021 | $8.55K | -84.14% |
| 2018 | $53.90K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Caladrius Biosciences Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $50.12K USD |
| MoneyControl | $50.12K USD |
| MarketWatch | $50.12K USD |
| marketcap.company | $50.12K USD |
| Reuters | $50.12K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.